Search

Your search keyword '"van der Wal, Marlot"' showing total 15 results
Start Over Author "van der Wal, Marlot"
15 results on '"van der Wal, Marlot"'

1. Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation

Author

Chao, Ying-Yin, Puhach, Alisa, Frieser, David, Arunkumar, Mahima, Lehner, Laurens, Seeholzer, Thomas, Garcia-Lopez, Albert, van der Wal, Marlot, Fibi-Smetana, Silvia, Dietschmann, Axel, Sommermann, Thomas, Ćiković, Tamara, Taher, Leila, Gresnigt, Mark S., Vastert, Sebastiaan J., van Wijk, Femke, Panagiotou, Gianni, Krappmann, Daniel, Groß, Olaf, and Zielinski, Christina E.

Published
2023
Full Text
View/download PDF

3. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy

Author

Unit Opleiding Dermatologie, Infection & Immunity, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), MS Dermatologie/Allergologie, CTI Research, Apotheek Opleiding, Apotheek KF TDM, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, Bakker, Daphne, Knol, Edward, van Luin, Matthijs, El Amrani, Mohsin, Delemarre, Eveline, Elfiky, Ahmed M I, de Boer, Joke, van Wijk, Femke, de Graaf, Marlies, de Bruin-Weller, Marjolein, Unit Opleiding Dermatologie, Infection & Immunity, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), MS Dermatologie/Allergologie, CTI Research, Apotheek Opleiding, Apotheek KF TDM, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, Bakker, Daphne, Knol, Edward, van Luin, Matthijs, El Amrani, Mohsin, Delemarre, Eveline, Elfiky, Ahmed M I, de Boer, Joke, van Wijk, Femke, de Graaf, Marlies, and de Bruin-Weller, Marjolein

Published
2024

4. Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

Author

Mijnheer, Gerdien, Lutter, Lisanne, Mokry, Michal, van der Wal, Marlot, Scholman, Rianne, Fleskens, Veerle, Pandit, Aridaman, Tao, Weiyang, Wekking, Mark, Vervoort, Stephin, Roberts, Ceri, Petrelli, Alessandra, Peeters, Janneke G. C., Knijff, Marthe, de Roock, Sytze, Vastert, Sebastiaan, Taams, Leonie S., van Loosdregt, Jorg, and van Wijk, Femke

Published
2021
Full Text
View/download PDF

5. Ocular surface disease in moderate‐to‐severe atopic dermatitis patients and the effect of biological therapy.

Author

Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, Bakker, Daphne, Knol, Edward, van Luin, Matthijs, El Amrani, Mohsin, Delemarre, Eveline, Elfiky, Ahmed M I, de Boer, Joke, van Wijk, Femke, de Graaf, Marlies, and de Bruin‐Weller, Marjolein

Subjects
ATOPIC dermatitis, BIOTHERAPY, ECZEMA, DUPILUMAB, SKIN diseases, MEDICAL personnel
Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment with these new targeted treatments, more insight into the occurrence and pathomechanism of OSD in moderate‐to‐severe AD patients is needed. Therefore, this review's first part highlights that most patients with moderate‐to‐severe AD already have characteristics of OSD before starting targeted treatment. Remarkably, not all AD patients with OSD report ocular symptoms. OSD in AD is associated with less conjunctival goblet cells (GC) compared to healthy controls. In addition, OSD severity in AD patients is associated with high AD activity, the presence of eyelid and/or facial eczema, and high levels of AD‐related severity biomarkers in tear fluid. The second part of this review highlights that pre‐existing ocular pathology (e.g. in combination with the use of ophthalmic medication or eyelid eczema) may be associated with the development of dupilumab‐associated ocular surface disease (DAOSD). During dupilumab treatment, DAOSD (which can be new‐onset OSD or worsening of pre‐existing OSD) is observed in approximately one‐third of the dupilumab‐treated AD patients. Anti‐inflammatory ophthalmic treatment improves DAOSD, and dose reduction of dupilumab may also be an effective treatment option. The pathomechanism of DAOSD is still not fully elucidated. In a prospective study low, but stable conjunctival GC numbers were observed in moderate‐to‐severe AD patients, before and during dupilumab treatment. However, the Mucin 5 AC (MUC5AC) expression of GCs decreased during dupilumab treatment, suggesting an impairment of the GC function by dupilumab treatment. In addition, higher dupilumab tear fluid levels were found in dupilumab‐treated AD patients with moderate‐to‐severe OSD compared to patients with no or mild OSD, whereas the dupilumab serum levels are similar. Clinicians should be aware of the frequent occurrence of OSD in moderate‐to‐severe AD patients, and a low‐threshold referral to an ophthalmologist is recommended. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Dupilumab-associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

Author

Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, de Bruin-Weller, Marjolein, Infection & Immunity, MS Dermatologie/Allergologie, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, and de Bruin-Weller, Marjolein

Published
2023

7. High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Apotheek Klinische Farmacie, Apotheek KF TDM, CTI Research, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, van Luin, Matthijs, El Amrani, Mohsin, Knol, Edward, Delemarre, Eveline, Jager, Constance den Hartog, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, de Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, CTI Van Wijk, MS Oogheelkunde, Other research (not in main researchprogram), Apotheek Klinische Farmacie, Apotheek KF TDM, CTI Research, CTI Bont, Child Health, Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, van Luin, Matthijs, El Amrani, Mohsin, Knol, Edward, Delemarre, Eveline, Jager, Constance den Hartog, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, and de Bruin-Weller, Marjolein

Published
2023

8. Dupilumab‐associated ocular surface disease in atopic dermatitis patients: clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

Author

Achten, Roselie, primary, Thijs, Judith, additional, van der Wal, Marlot, additional, van Luijk, Chantal, additional, de Graaf, Marlies, additional, Bakker, Daphne, additional, de Boer, Joke, additional, van Wijk, Femke, additional, and de Bruin‐Weller, Marjolein, additional

Published
2023
Full Text
View/download PDF

9. High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease

Author

Achten, Roselie, primary, Thijs, Judith, additional, van der Wal, Marlot, additional, van Luijk, Chantal, additional, van Luin, Matthijs, additional, el Amrani, Mohsin, additional, Knol, Edward, additional, Delemarre, Eveline, additional, Jager, Constance den Hartog, additional, de Graaf, Marlies, additional, Bakker, Daphne, additional, de Boer, Joke, additional, van Wijk, Femke, additional, and de Bruin‐Weller, Marjolein, additional

Published
2023
Full Text
View/download PDF

10. Human Th17 cells engage gasdermin E pores to release IL-1a upon NLRP3 inflammasome activation

Author

Chao, Ying-Yin, Puhach, Alisa, Frieser, David, Arunkumar, Mahima, Lehner, Laurens, Seeholzer, Thomas, Garcia-Lopez, Albert, Van der Wal, Marlot, Fibi-Smetana, Silvia, Dietschmann, Alex, Sommermann, Thomas, Ćiković, Tamara, Taher, Leila, Gresnigt, Mark S., Vastert, Sebastiaan J., Van Wijk, Femke, Panagiotou, Gianni, Krappmann, Daniel, Groß, Olaf, and Zielinski, Christina E.

Subjects
Th17, cytokine, IL-1a, inflammasome, gasdermin E, inflammation
Abstract

There is evidence that innate immune responses coopt adaptive properties such as memory. Whether T cells harness innate immune signaling pathways to diversify their repertoire of effector functions remains unknown. Here, we found that human T cells expressed gasdermin E (GSDME), a membrane pore-forming molecule that has recently been shown to execute pyroptotic cell death and thus to serve as a potential cancer checkpoint. In T cells, GSDME expression was, in contrast, associated with durable viability and was repurposed for the tunneled release of the alarmin IL-1a. This property was restricted to a subset of human Th17 cells with specificity for C. albicans and was regulated by a T cell-intrinsic NLRP3 inflammasome and its engagement of a proteolytic cascade of successive caspase-8, caspase-3 and GSDME cleavage following T-cell receptor stimulation and calcium-licensed calpain maturation of the pro-IL1a form. Our results propose GSDME pore formation in T cells as a mechanism of unconventional cytokine release through harnessing of innate signaling platforms in response to adaptive stimuli. This finding diversifies the functional repertoire and mechanistic equipment of T cells with implications for anti-fungal host defense.

Published
2022
Full Text
View/download PDF

12. ZFP36 family members regulate the pro-inflammatory features of psoriatic dermal fibroblasts

Author

CTI Van Loosdregt, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Reumat./Klin. Immunologie, Lab Reumatologie/Klinische Immunologie, CTI CFF, CTI Van Wijk, Unit Opleiding Dermatologie, MS Dermatologie/Allergologie, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Angiolilli, Chiara, Leijten, Emmerik F A, Bekker, Cornelis P J, Eeftink, Ella, Giovannone, Barbara, Nordkamp, Michel Olde, van der Wal, Marlot, Thijs, Judith L, Vastert, Sebastiaan J, van Wijk, Femke, Radstake, Timothy R D J, van Loosdregt, Jorg, CTI Van Loosdregt, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Unit Opleiding Reumat./Klin. Immunologie, Lab Reumatologie/Klinische Immunologie, CTI CFF, CTI Van Wijk, Unit Opleiding Dermatologie, MS Dermatologie/Allergologie, Immuno/reuma onderzoek 5 (Vastert2), Child Health, CTI Research, Immuno/reuma onderzoek 3 (Loosdregt), Angiolilli, Chiara, Leijten, Emmerik F A, Bekker, Cornelis P J, Eeftink, Ella, Giovannone, Barbara, Nordkamp, Michel Olde, van der Wal, Marlot, Thijs, Judith L, Vastert, Sebastiaan J, van Wijk, Femke, Radstake, Timothy R D J, and van Loosdregt, Jorg

Published
2022

13. Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients

Author

Achten, Roselie E., primary, Bakker, Daphne S., additional, van Luijk, Chantal M., additional, van der Wal, Marlot, additional, de Graaf, Marlies, additional, van Wijk, Femke, additional, Zuithoff, Nicolaas P.A., additional, van der Rijst, Lisa P., additional, Boesjes, Celeste M., additional, Thijs, Judith L., additional, de Boer, Joke H., additional, and de Bruin‐Weller, Marjolein S., additional

Published
2022
Full Text
View/download PDF

14. Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation

Author

Infection & Immunity, MMB Research line 1, CTI Van Wijk, Onderzoek Precision medicine, Child Health, Circulatory Health, CTI Van Loosdregt, CTI Pandit, Lab Reumatologie/Klinische Immunologie, CTI Research, CMM Groep Coffer, Immuno/reuma onderzoek 1 (Vastert), Immuno/reuma onderzoek 5 (Vastert2), Immuno/reuma onderzoek 3 (Loosdregt), Mijnheer, Gerdien, Lutter, Lisanne, Mokry, Michal, van der Wal, Marlot, Scholman, Rianne, Fleskens, Veerle, Pandit, Aridaman, Tao, Weiyang, Wekking, Mark, Vervoort, Stephin, Roberts, Ceri, Petrelli, Alessandra, Peeters, Janneke G C, Knijff, Marthe, de Roock, Sytze, Vastert, Sebastiaan, Taams, Leonie S, van Loosdregt, Jorg, van Wijk, Femke, Infection & Immunity, MMB Research line 1, CTI Van Wijk, Onderzoek Precision medicine, Child Health, Circulatory Health, CTI Van Loosdregt, CTI Pandit, Lab Reumatologie/Klinische Immunologie, CTI Research, CMM Groep Coffer, Immuno/reuma onderzoek 1 (Vastert), Immuno/reuma onderzoek 5 (Vastert2), Immuno/reuma onderzoek 3 (Loosdregt), Mijnheer, Gerdien, Lutter, Lisanne, Mokry, Michal, van der Wal, Marlot, Scholman, Rianne, Fleskens, Veerle, Pandit, Aridaman, Tao, Weiyang, Wekking, Mark, Vervoort, Stephin, Roberts, Ceri, Petrelli, Alessandra, Peeters, Janneke G C, Knijff, Marthe, de Roock, Sytze, Vastert, Sebastiaan, Taams, Leonie S, van Loosdregt, Jorg, and van Wijk, Femke

Published
2021

15. Conserved human effector Treg signature is reflected in transcriptomic and epigenetic landscape

Author

Mijnheer, Gerdien, primary, Lutter, Lisanne, additional, Mokry, Michal, additional, van der Wal, Marlot, additional, Fleskens, Veerle, additional, Scholman, Rianne, additional, Pandit, Aridaman, additional, Tao, Weiyang, additional, Wekking, Mark, additional, Vervoort, Stephin, additional, Roberts, Ceri, additional, Petrelli, Alessandra, additional, Peeters, Janneke G.C., additional, Knijff, Marthe, additional, de Roock, Sytze, additional, Vastert, Sebastiaan, additional, Taams, Leonie S., additional, van Loosdregt, Jorg, additional, and van Wijk, Femke, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results